Surmodics Acquires Embolitech's Thrombectomy Technology Assets

 

May 14, 2018—Surmodics, Inc. announced that it has reached an agreement to acquire Embolitech's thrombectomy platform technology and related intellectual property, which have broad potential peripheral vascular applications. Under the agreement, Surmodics will pay $5 million up front and additional amounts related to various regulatory milestones.

The Embolitech platform is designed to remove difficult, organized blood clots. Surmodics will leverage its design, development, and manufacturing capabilities to advance the technology platform for a variety of peripheral and vascular applications.

According to Surmodics, the Embolitech technology may eliminate the need for the use of thrombolytics, reducing intensive care unit time and bleeding complications that significantly affect patient recovery and outcomes. In addition, the technology is anticipated to reduce procedure time and the need for multiple procedures, and it does not require any additional, external capital equipment.

Gary Ansel, MD, the Founder and Chief Medical Officer of Embolitech, commented in the announcement, “We are pleased to sign an agreement with Surmodics for this promising thrombus management platform that complements their current portfolio and aligns well with their focus on advancing therapies for peripheral artery disease.”

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.